Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status
/in Hyperthermia, International Publications, Soft Tissue SarcomaTumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian CancerRegression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
/in Dendritic Cells, International Publications, Urothelial CarcinomaPhase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
/in Dendritic Cells, International Publications, Prostate CancerRadiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group
/in Breast Cancer, Hyperthermia, International PublicationsEffect of whole-body hyperthermia on AIDS patients with Kaposi’s sarcoma: a pilot study
/in HIV/AIDS, International PublicationsFeasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer
/in Hyperthermia, International Publications, Urothelial CarcinomaHyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology
/in Hyperthermia, International Publications, Malignant LymphomaHyperthermia–its actual role in radiation oncology. Part IV: Thermo-radiotherapy for malignant brain tumors
/in Glioblastoma, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer